Press Room

New Data Affirms Value of Breast Cancer Index (BCI) in Identification of Early Stage ER+ Breast Cancer Patients Appropriate for Extended Endocrine Therapy (EET)
Biotheranostics, Inc. today announced new data further demonstrating the importance of BCI in clinical practice. In a study of more than 14,000 cases…
Biotheranostics Appoints Don Hardison as New CEO
Biotheranostics, Inc., a growing molecular diagnostics company, today announced the appointment of Don Hardison as Chief Executive Officer…
Biotheranostics Presents First Data from the BCI Clinical Database for Correlative Studies
A recent analysis from the newly developed Breast Cancer Index (BCI) Clinical Database for Correlative Studies was presented at the 18th American Society of Breast Surgeons Annual Meeting in Las Vegas, NV…
Breast Cancer Index SM (BCI) Included in Updated Guidelines for Use of Clinical Biomarkers in Breast Cancer
New guidelines recently published by the European Group on Tumor Markers (EGTM) recommend that the validated biomarker, Breast Cancer IndexSM (BCI), may be…
Study Demonstrates Use of Breast Cancer IndexSM (BCI) Leads to Significant Changes in Physician Recommendations for Extended Endocrine Therapy in ER+ Breast Cancer Patients
Results from a new multi-institutional study assessing the role of Breast Cancer IndexSM (BCI) in treatment decision-making for ER+ breast cancer patients who are considering…
Study Presented at San Antonio Breast Cancer Symposium Demonstrates Strong Performance of Biotheranostics’ 92-gene Assay in the Diagnosis of Triple Negative Breast Cancer
A study showing the strong performance of an optimized version of…
Breast Cancer IndexSM Predicted Patients at High Risk of Recurrence Despite Low Risk Clinical Features, New Data Suggest
Results from new analyses of two cohorts demonstrate that Breast Cancer Index (BCI), a genomic biomarker performed by Biotheranostics, Inc.…
New Data Substantiate the Ability of Breast Cancer IndexSM to Help Physicians Identify Early Stage ER+ Breast Cancer Patients for Extended Anti-Estrogen Therapy
Biotheranostics today announced that new data will be presented demonstrating the role of the Breast Cancer Index (BCI) in identifying which patients with early stage, ER+ breast cancer are…
Biotheranostics & Syapse Collaborate to Integrate Genomics-Based Molecular Diagnostics for Cancer into the Syapse Precision Medicine Platform
Biotheranostics, Inc., a pioneer in molecular diagnostics for cancer, and Syapse, the leader in precision medicine software…
Biotheranostics Appoints Industry Veteran Don Hardison to Board of Directors
Biotheranostics, Inc., today announced that Don Hardison has been appointed to its Board of Directors…
Biotheranostics’ Announces New Data Presented at 2016 ASCO Annual Meeting
Biotheranostics announced new independent data validating a new Breast Cancer Index (BCI)…
Study Presented at ASCO 2016 Shows Clinical Utility of Biotheranostics’ CancerTYPE ID® in Predicting Tumor Type & Aiding in Treatment Optimization for Metastatic Cancer Patients
A study demonstrating the clinical utility of Biotheranostics’ CancerTYPE® ID molecular cancer classifier…